BioAtla BCAB
OTC BCAB
$1.45 +0.12 (+9.02%)
As of: Oct 21, 2026 · 12:24 PM EDT

BioAtla (BCAB) EBITDA Margin (2020 - 2026)

Updated

BioAtla (BCAB) recorded EBITDA Margin of 3.49% in Q2 2026.

Analysis

BioAtla (BCAB) EBITDA Margin (2020 - 2026) Analysis & Trends

On a TTM basis, BioAtla's EBITDA Margin came in at -375.65% as of Jun 30, 2026, up 197.27 percentage points year-over-year; for FY2025, it was -2946.60%, down 2282.80 percentage points from FY2024.

  • Annual EBITDA Margin has a five-year change of +3834.52 percentage points (FY2020 to FY2025).
  • Across earlier years, EBITDA Margin came in at -663.80% in FY2024 and -38044.00% in FY2021 (-31262.88 pp).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 35.95%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 49.01%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.11%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -124.26%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 39.16%
10 BioAtla 2.41 Mn -16.54 Mn - 3.49%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.49%
Dec 31, 2025 -461.80%
Sep 30, 2024 -100.38%
Jun 30, 2024 -2,415.89%
Jun 30, 2021 -12,053.20%
Sep 30, 2020 -5,153.33%
Jun 30, 2020 -2,265.79%
Mar 31, 2020 -1,003.37%
API Access

BioAtla EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=BCAB&period=max&api_key=YOUR_API_KEY